Sunday, June 5, 2016

8:30 am – 9:15 am

KEYNOTE: Long-term Opioid Use in Supportive Care Clinics:  Assessment and Monitoring Among Patients with Advanced Cancer and Cancer Survivors

Eduardo Bruera, MD

9:15 am – 10:00 am

Kappa Opioid Receptor Agonists (KORAs), a Novel Pharmacology for the Treatment of Acute and Chronic Pain

Joseph Stauffer, DO, MBA

TJ Gan, MD, MHS, FRCA

Lynn Webster, MD

Three experts in the field of clinical research and clinical practice will describe the pre-clinical and clinical data for novel peripherally selective Kappa Opioid Receptor Agonists (KORAs). Human Abuse Liability data will also be presented. Application of this novel pharmacology may fill an unmet need in acute and chronic pain.

10:00 am – 10:30 am Break with Exhibitors and Poster Presenters

10:30 am – 11:15 am

Medication Assisted Treatment for Opioid Use Disorders that Occur in the Treatment of Chronic Pain

Elinore McCance-Katz, MD, PhD

The occurrence of opioid use disorder (OUD, opioid abuse/addiction) is a concern shared by many clinicians who prescribe opioids in the context of pain management. This presentation will review literature on rates of OUD in chronic pain patients, behaviors associated with OUD, the validity of the construct of psuedoaddiction, epidemiology of OUD in Americans and treatment of OUD. Medication assisted treatment for OUD in the context of the patient with pain will be addressed as will new models of care for this population.

11:15 am – 12:00 pm

Opioids for Chronic Pain:“Damned if You Do, Damned If You Don’t!”

Howard A. Heit, MD, FACP, FASAM

12:00 pm – 12:30 pm

Association of Single-Nucleotide Polymorphisms, Buprenorphine vs Methadone Maintenance Therapy, and Second/Third Trimester Dose Reduction Strategies with Clinical Outcomes of Neonatal Abstinence Syndrome

John Standridge, M.D. DFASAM

 

Four specific objectives include:  To determine whether genomic variations in the mothers are associated with severity of Neonatal Abstinence Syndrome (NAS); To confirm the findings of the MOTHER trial; To demonstrate that a tapering regimen is safe and effective in proactively alleviating NAS severity; To create an NAS risk index.

12:30 pm - 1:30 pm

Lunch Break with Exhibitors, Poster Presenters or Satellite Symposia

Lunch provided by ICOO2016 organizers - not industry sponsored

1:30 pm – 2:15 pm

Opioids and Clinical Cannabis:  Considerations in Co-occurring Use

Seddon Savage MD, MS

Gil Fanciullo MD, MS

 

Twenty-three U.S. States and all Canadian provinces have made herbal cannabis available for clinical management of pain and a variety of other symptoms and many patients prescribed opioids for pain elect to also use marijuana either through legal authorization or illicitly. Opioids and cannabis/cannabinoids provide analgesia through different mechanisms and both are rewarding substances that can become objects of diversion, misuse and addiction. This raises numerous clinical considerations for clinicians who use opioids to treat pain, particularly in States with legal access to marijuana. Whether or not physicians support use of non-pharmaceutical cannabis in clinical care, most will need to manage patients who elect to use cannabis for pain control.

2:15 pm – 3:15 pm

Contemporary Issues in Opioid Therapy

 

• Methadone: Refining and Defining Safety and Efficacy in Clinical Practice
• One Size Really Doesn't Fit All: Implications of patient- and opioid-specific variables
• It's more than a number...Advanced opioid conversions and dosing strategies

Mary Lynn McPherson, PharmD, BCPS, CPE

Kathryn Walker, PharmD

 

The American Pain Society and other groups recently published safety guidelines on methadone dosing and suggested monitoring parameters. This presentation will provide an overview of these guidelines and will include case-based illustrative examples. Application in special populations such as end of life care will also be addressed.

Practitioners are fortunate to have multiple opioids to select from to treat patients with moderate to severe pain. No one opioid is the best choice for any individual patient. Participants in this session will learn how to consider characteristics about various opioids, and specific patients to make optimal decisions.

Calculating opioid conversions can be complex, but are commonly coupled with the challenge of applying it to a medically complicated patient. To address this issue, we will discuss case based pearls to use in untangling the complexities of applying opioid conversions to patient care.

3:15 pm – 3:30 pm

Predictors of Intubation and Death; a Review of 453 Cases of Methadone Toxicity in Children

Nasim Zamani, MD

Hossein Hassanian-Moghaddam (MD)

 

Methadone toxicity is a major cause of mortality and morbidity in Iranian Population. In the recent years, number of cases with methadone toxicity has increased especially among children. The main cause of its increased rate of toxicity among children is greater accessibility through their addicted parents.

 

3:30 pm – 4:00 pm - Break with Exhibitors and Poster Presenters

4:00 pm – 5:00 pm

The Evolution of Abuse Deterrent Drug Formulations:  Testing effectiveness from the benchtop to the real world

Beatrice Setnik, PhD

James Tolliver, PhD

Richard Dart, MD, PhD

Edward Cone, PhD

 

ICOO participants will greatly benefit from understanding the regulatory requirements and evolving methods for evaluating abuse deterrent formulations and the emerging data to determine if an abuse deterrent approach is effective in mitigating prescription opioid abuse and misuse in the real world.

5:00 pm – 5:30 pm

ER/LA Opioid Analgesics REMS: Implementation and Impact on Opioid Abuse, Overdose and Death

Paul Coplan ScD, MBA

Gregory Wedin PharmD, DABAT

Laura Wallace MPH

 

This symposium will describe the components and results of the extended-release/long-acting (ER/LA) opioid class risk evaluation and mitigation strategy (REMS) program. It will include details on the class-REMS collaboration and structure, REMS education, metrics, results, and overall impacts on opioid prescribing and abuse in the United States.

 

6:00 pm – 8:00 pm

SCREENING: "The Painful Truth: What Chronic Pain Is Really Like and Why It Matters to Each of Us"

Lynn Webster, MD

Dr. Lynn Webster has dedicated more than three decades to becoming an expert in the field of pain management. A leading voice in trying to help physicians safely treat pain patients, Dr. Webster actively works within the industry to develop safer and more effective therapies for chronic pain and addiction. In The Painful Truth, Dr. Webster introduces chronic pain through the eyes of his former patients, illustrating their unique situations as their lives were suddenly and dramatically torn apart by onset pain.

8:00 am - 8:45 am

NATIONAL PAIN STRATEGY: Implications for the Pain Community

Daniel Carr, MD, FABPM

 8:45 am - 9:30 am

CDC Guidelines

Jane Ballantyne, MD

 9:30 – 10:00 am

Selected Case Studies and the Application of Recent Guidelines

Jane Ballantyne, MD

Daniel Carr, MD, FABPM

Lynn Webster, MD

10:00 am – 10:30 am - Break with Exhibitors and Poster Presenters

10:30 am - 11:00 am

Reduction in postoperative opioid requirement through the combined application of preoperative risk assessment and multimodal analgesia.

Guy Hans, MD, PhD

 

Scientific update on practices to reduce opioid requirement postoperatively with application of preoperative risk assessment and application of multimodal analgesic methods per- en post-operatively.

11:00 am - 11:45 am

If Not You, Who? A Call for Informed Professionals To Engage in Opioid-Related Policy Making

Michael Barnes

Jonathan Young

 

A discussion of timely opioid-related policy matters and a call to action

11:45 am - 12:00 pm

Reducing the community prescribed opioid load as a harm reduction strategy

Kieran Moore, MD, CCFP(EM), FCFP, MPH, DTM&H, FRCPC

 

This presentation will introduce a new community safety strategy to reduce the harm imposed by opioids on communities, and help to control the opioid epidemic. Our concept of a community prescribed opioid load encourages best practice in opioid prescribing and monitoring to reduce the quantity of opioids in circulation.

12:00 pm - 12:30 pm

New Drugs in Opioid-Induced Constipation: How Much is That Bowel Movement Gonna Cost You?

Leah Sera, PharmD, BCPS

Nina M. Bemben, PharmD, BCPS

Opioid-induced constipation (OIC) is a common and distressing symptom in patients with advanced illness taking opioids. This presentation will describe the pharmacology of newer agents for constipation, assess the evidence for their use in OIC, and discuss their place in therapy.

 12:30 pm - 1:30 pm

Lunch Break with Exhibitors, Poster Presenters or Satellite Symposia

Lunch provided by ICOO2016 organizers - not industry sponsored

1:30 pm - 2:15 pm

Legal Issues from a Physician’s Viewpoint

Carol Warfield, MD

2:15 pm - 3:30 pm

Effective Treatment vs Enabling: Where to Draw the Line with Opioid Agonist Therapy?

Joseph Insler, MD

Anna LaRose, MD

Akiva Daum, MD

John Renner, MD

 

This workshop will focus on buprenorphine maintenance treatment in patients who continue to abuse opioids or other drugs. These patients often create clinical challenges since many do not achieve sobriety in their initial treatment attempts, and providers may wonder whether they are helping or harming by continuing maintenance treatment.

3:30 pm – 4:00 pm - Break with Exhibitors and Poster Presenters

 
4:00 pm - 5:30 pm

Evidence-Based Best Practice for Opioid Prescribing and Monitoring: Medicolegal Pain Management Expert Symposium

Daniel Schwarz, MD, FASAM

Ronald Chapman, II, JD

Jodi Debbrecht Switalksi, JD

 

Media’s lopsided heroin consequences contradict persistent opiate prescriptions, emergency visits and mortality.  Despite varied state legislation and disparaging new mandates, the prescription opioid epidemic is thriving.  Requiring objective functional pain metrics, knowledge of judicial actions and review of pertinent case law, realistic solutions for prevention may prevail over societal band-aid solutions.

Tuesday, June 7, 2016

8:00 am - 8:30 am

Behavioral Interventions for Pain Management

Robert Jamison, PhD

8:30 am - 8:45 am

How to wean patients of opioids: what resources can be used to educate and support patients to cease taking opioids.

Penny Briscoe MBBS FPMANZCA

With increasing concerns of harm and evidence of poor efficacy from long term use of opioids in chronic non-malignant pain how can we advise and support patients to wean?

What are some of the tools that can be used to help patients understand why we wish them to wean.

 

8:45 am - 9:15 am

The disciplinary process for physicians who are reported for poor opioid prescribing practices

James McDonald, MD, MPH

9:15 am -10:00 am

KEYNOTE: The role and perspective of State Medical Boards in the oversight of chronic opioid therapy for pain management.

Humayun Chaudhry, D.O., MACP, MACOI

10:00 am – 10:30 am - Break with Exhibitors

10:30 am – 11:00 am

Top Three Posters

11:00 am – 12:30 pm

Governors’ Panel

Gov. Gina M. Raimondo

Gov. Paul R. LePage

Gov. Peter E. Shumlin

ICOO 2016 Conference Wrap Up

---------------------------